ATE404178T1 - Vorrichtung mit matrixgesteuerter wirkstofffreisetzung - Google Patents

Vorrichtung mit matrixgesteuerter wirkstofffreisetzung

Info

Publication number: ATE404178T1
Authority: AT; Austria
Prior art keywords: matrix; active release; controlled active; spray; dosage form
Prior art date: 1999-02-10

Application number

AT00300546T

Other languages

English (en)

Inventor

Leah Elizabeth Appel

Dwayne Thomas Friesen

William John Curatolo

James Alan Schrive Nightingale

Avinash Govind Thombre

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-10

Filing date

2000-01-26

Publication date

2008-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22384221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE404178(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-01-26 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2008-08-15 Application granted granted Critical

2008-08-15 Publication of ATE404178T1 publication Critical patent/ATE404178T1/de

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
239000002552 dosage form Substances 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 2
239000011159 matrix material Substances 0.000 abstract 2
238000013270 controlled release Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229920000642 polymer Polymers 0.000 abstract 1
239000007962 solid dispersion Substances 0.000 abstract 1
239000007921 spray Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Immunology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Virology (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Nutrition Science (AREA)
Hospice & Palliative Care (AREA)
Tropical Medicine & Parasitology (AREA)

AT00300546T 1999-02-10 2000-01-26 Vorrichtung mit matrixgesteuerter wirkstofffreisetzung ATE404178T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11940099P	1999-02-10	1999-02-10

Publications (1)

Publication Number	Publication Date
ATE404178T1 true ATE404178T1 (de)	2008-08-15

Family

ID=22384221

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00300546T ATE404178T1 (de)	1999-02-10	2000-01-26	Vorrichtung mit matrixgesteuerter wirkstofffreisetzung

Country Status (7)

Country	Link
EP (1)	EP1027887B1 (de)
JP (2)	JP4355779B2 (de)
AT (1)	ATE404178T1 (de)
BR (1)	BR0000359A (de)
CA (1)	CA2298245C (de)
DE (1)	DE60039802D1 (de)
ES (1)	ES2310164T3 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2000281561A (ja) *	1999-03-26	2000-10-10	Ajinomoto Co Inc	新規溶媒法固体分散体製剤
DZ3227A1 (fr) *	1999-12-23	2001-07-05	Pfizer Prod Inc	Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
UY26615A1 (es)	2000-03-16	2001-10-25	Pfizer Prod Inc	Inhibidor de la glucogeno fosforilasa.
DE10026698A1 (de)	2000-05-30	2001-12-06	Basf Ag	Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
KR20020014570A (ko) *	2000-08-18	2002-02-25	김충섭	고체분산화시킨 무정형 이프리플라본의 제조방법
GB0027357D0 (en)	2000-11-09	2000-12-27	Bradford Particle Design Plc	Particle formation methods and their products
JP2005500313A (ja)	2001-06-22	2005-01-06	ファイザー・プロダクツ・インク	基材中の低可溶性薬物の固体分散体および溶解度向上性ポリマーを含有する医薬品組成物
MXPA03011784A (es)	2001-06-22	2004-04-02	Pfizer Prod Inc	Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
MXPA03011935A (es) *	2001-06-22	2004-03-26	Pfizer Prod Inc	Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
EP1269994A3 (de)	2001-06-22	2003-02-12	Pfizer Products Inc.	Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
JP4547148B2 (ja) *	2001-06-22	2010-09-22	ベンド・リサーチ・インコーポレーテッド	非晶質薬剤の吸着物の医薬組成物
WO2003000292A1 (en)	2001-06-22	2003-01-03	Pfizer Products Inc.	Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
WO2003007968A1 (en) *	2001-07-17	2003-01-30	Sun Pharmaceutical Industries Ltd.	A cardiotonic composition
US20030099708A1 (en) *	2001-10-29	2003-05-29	Therics, Inc	Printing or dispensing a suspension such as three-dimensional printing of dosage forms
AU2002217373A1 (en) *	2002-01-03	2003-07-15	Lek Pharmaceutical And Chemical Company D.D.	Controlled release pharmaceutical formulation containing venlafaxine
CN1688291A (zh)	2002-02-01	2005-10-26	辉瑞产品公司	含有固体药物分散体的即刻释放剂型
KR100664822B1 (ko)	2002-02-01	2007-01-04	화이자 프로덕츠 인코포레이티드	변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
WO2003063833A1 (en)	2002-02-01	2003-08-07	Pfizer Products Inc.	Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
JP2005523260A (ja)	2002-02-01	2005-08-04	ファイザー・プロダクツ・インク	圧力ノズルを用いた均質噴霧乾燥固体非晶質薬剤分散体の製造方法
PL371416A1 (en) *	2002-02-01	2005-06-13	Pfizer Products Inc.	Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
EP1505987A2 (de) *	2002-05-13	2005-02-16	Pharmacia Corporation	Stabile amorphe celecoxib komposite und verfahren deren
SI21223A (sl) *	2002-06-19	2003-12-31	Krka, Tovarna Zdravil, D.D., Novo Mesto	Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom
AU2003249474A1 (en) *	2002-08-12	2004-02-25	Pfizer Products Inc.	Pharmaceutical compositions of semi-ordered drugs and polymers
WO2004069180A2 (en)	2003-01-31	2004-08-19	Smithkline Beecham Corporation	Solid dispersion compositions
IL154370A0 (en) *	2003-02-10	2003-09-17	Chemagis Ltd	Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
DE10325989A1 (de) *	2003-06-07	2005-01-05	Glatt Gmbh	Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
KR20060033033A (ko) *	2003-08-04	2006-04-18	화이자 프로덕츠 인크.	콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출 및ｈｍｇ-ｃｏａ 리덕타제 억제제의 순간 방출을 제공하는제형
MXPA06001417A (es)	2003-08-04	2006-05-15	Pfizer Prod Inc	Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
CL2004001884A1 (es)	2003-08-04	2005-06-03	Pfizer Prod Inc	Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US8025899B2 (en)	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
US8377952B2 (en)	2003-08-28	2013-02-19	Abbott Laboratories	Solid pharmaceutical dosage formulation
AR048431A1 (es) *	2004-03-17	2006-04-26	Novartis Ag	Formulaciones galenicas de compuestos organicos
BRPI0514416A (pt) *	2004-08-31	2008-06-10	Pfizer Prod Inc	formas de dosagem de liberação controlada combinando liberação imediata e liberação controlada de um fármaco de baixa solubilidade
CA2577852A1 (en) *	2004-08-31	2006-03-09	Pfizer Products Inc.	Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
AU2005288521A1 (en)	2004-09-29	2006-04-06	Chemagis Ltd.	Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
US8481565B2 (en)	2004-12-27	2013-07-09	Eisai R&D Management Co., Ltd.	Method for stabilizing anti-dementia drug
US20090208579A1 (en) *	2004-12-27	2009-08-20	Eisai R & D Management Co., Ltd.	Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
WO2006079921A2 (en)	2005-01-28	2006-08-03	Pfizer Products Inc.	Drying of drug-containing particles
EP1845953A1 (de) *	2005-02-03	2007-10-24	Pfizer Products Incorporated	Darreichungsformen mit kontrollierter und unmittelbarer freisetzung von cholesterylester-transferprotein-hemmern und unmittelbarer freisetzung von hmg-coa-reduktase-hemmern
WO2007027494A2 (en) *	2005-08-29	2007-03-08	Sanofi-Aventis U.S. Llc	Morphous solid dispersions of 7-chloro-n,n, 5-trimethyl-4-oxo-3-phenyl-3, 5,-dihydro-4h-pyridazino [4, 5-b] indole-1-acetamide
PT2043610E (pt)	2006-07-21	2015-10-22	Bend Res Inc	Secagem de partículas contendo fármacos
PE20081506A1 (es)	2006-12-12	2008-12-09	Infinity Discovery Inc	Formulaciones de ansamicina
MX2009010568A (es) *	2007-04-03	2009-10-22	Reddys Lab Ltd Dr	Formas solidas de pemetrexed.
WO2008138755A2 (en) *	2007-05-11	2008-11-20	F. Hoffmann-La Roche Ag	Pharmaceutical compositions for poorly soluble drugs
JP5048398B2 (ja) *	2007-06-13	2012-10-17	大蔵製薬株式会社	抗真菌剤の医薬組成物
SMT202000093T1 (it)	2009-06-16	2020-03-13	Pfizer	Forme di dosaggio di apixaban
US8329208B2 (en)	2009-07-28	2012-12-11	Methylation Sciences International Srl	Pharmacokinetics of S-adenosylmethionine formulations
EP2524688B1 (de) *	2011-05-11	2013-05-01	ratiopharm GmbH	Zusammensetzung zur modifizierten Freisetzung mit Ranolazin
JO3339B1 (ar) *	2012-09-11	2019-03-13	Shanghai Inst Pharmaceutical Ind	شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
EP2949331A1 (de)	2012-10-17	2015-12-02	Methylation Sciences International SRL	Zusammensetzungen mit s-adenosylmethionin und einem gallussäureester
JP5836980B2 (ja)	2013-01-11	2015-12-24	信越化学工業株式会社	薬物含有粒子、固形製剤及び薬物含有粒子の製造方法
EP3076951B1 (de) *	2013-12-05	2020-09-30	Celal Albayrak	Verfahren zur herstellung von arzneimittelformulierungen zur oralen verabreichung
BR112016026046A8 (pt) *	2014-05-08	2021-07-20	Oncoethix Gmbh	uso de compostos de tienotriazolodiazepina
US12133911B2 (en)	2015-06-09	2024-11-05	Capsugel Belgium Nv	Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
GB201609222D0 (en)	2016-05-25	2016-07-06	F2G Ltd	Pharmaceutical formulation
US11819503B2 (en)	2019-04-23	2023-11-21	F2G Ltd	Method of treating coccidioides infection
US20220218719A1 (en) *	2019-05-17	2022-07-14	Glaxosmithkline Intellectual Property Development Limited	Matrix composition comprising (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
AU2020349524B2 (en) *	2019-09-18	2026-05-07	Bristol-Myers Squibb Company	Dosage forms for Tyk2 inhibitors
EP4712796A2 (de)	2023-05-15	2026-03-25	Bonafide Health, LLC	Schlafverbessernde zusammensetzungen und verfahren zur verwendung
AU2024344754A1 (en)	2023-09-21	2026-04-02	Takeda Pharmaceutical Company Limited	Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
WO2026033474A1 (en)	2024-08-08	2026-02-12	Takeda Pharmaceutical Company Limited	Deuterated compounds and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5649314A (en) *	1979-07-05	1981-05-02	Yamanouchi Pharmaceut Co Ltd	Lasting pharmaceutical composition having prolonged action and its preparation
JPS5948810B2 (ja) *	1980-03-22	1984-11-29	山之内製薬株式会社	ニカルジピン持続性製剤用組成物
JPS58116414A (ja) *	1981-12-23	1983-07-11	Yamanouchi Pharmaceut Co Ltd	ニカルジピン持続性製剤用球形顆粒およびその製造法
JP2528706B2 (ja) *	1988-05-30	1996-08-28	ゼリア新薬工業株式会社	ジヒドロピリジン化合物の製剤組成物
TW212139B (de) *	1991-04-15	1993-09-01	Yamanouchi Pharma Co Ltd
IT1250654B (it) *	1991-07-08	1995-04-21	Farcon Ag	Metodo per la preparazione di forme farmaceutiche orali a rilascio prolungato contenenti sostanze attive a solubilita' dipendente dal valore di ph.
JP2516524B2 (ja) *	1992-04-27	1996-07-24	大洋薬品工業株式会社	持続性製剤
US5773025A (en) *	1993-09-09	1998-06-30	Edward Mendell Co., Inc.	Sustained release heterodisperse hydrogel systems--amorphous drugs
EP0758244B2 (de) *	1994-05-06	2008-02-13	Pfizer Inc.	Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
DE19515972A1 (de) *	1995-05-02	1996-11-07	Bayer Ag	Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung
IE80467B1 (en) *	1995-07-03	1998-07-29	Elan Corp Plc	Controlled release formulations for poorly soluble drugs
TW487582B (en) *	1995-08-11	2002-05-21	Nissan Chemical Ind Ltd	Method for converting sparingly water-soluble medical substance to amorphous state
DK0901786T3 (da) *	1997-08-11	2007-10-08	Pfizer Prod Inc	Faste farmaceutiske dispersioner med foröget biotilgængelighed

2000
- 2000-01-26 AT AT00300546T patent/ATE404178T1/de not_active IP Right Cessation
- 2000-01-26 DE DE60039802T patent/DE60039802D1/de not_active Expired - Lifetime
- 2000-01-26 EP EP00300546A patent/EP1027887B1/de not_active Expired - Lifetime
- 2000-01-26 ES ES00300546T patent/ES2310164T3/es not_active Expired - Lifetime
- 2000-02-09 CA CA002298245A patent/CA2298245C/en not_active Expired - Lifetime
- 2000-02-10 JP JP2000033446A patent/JP4355779B2/ja not_active Expired - Fee Related
- 2000-02-10 BR BR0000359-0A patent/BR0000359A/pt not_active Application Discontinuation
2005
- 2005-08-04 JP JP2005226695A patent/JP4694298B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
BR0000359A (pt)	2001-08-14
JP4694298B2 (ja)	2011-06-08
DE60039802D1 (de)	2008-09-25
CA2298245A1 (en)	2000-08-10
CA2298245C (en)	2004-11-30
ES2310164T3 (es)	2009-01-01
EP1027887A2 (de)	2000-08-16
JP2000229888A (ja)	2000-08-22
EP1027887B1 (de)	2008-08-13
EP1027887A3 (de)	2001-02-28
JP4355779B2 (ja)	2009-11-04
JP2005320354A (ja)	2005-11-17

Legal Events

Date	Code	Title	Description
2009-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60039802D1 (de)	2008-09-25	Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
DE69809222D1 (de)	2002-12-12	Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron-vorläuferverbindungen
BR0000358A (pt)	2001-08-21	Liberação controlada por extrusão de dispersões amorfas sólidas de drogas
CY1109489T1 (el)	2014-08-13	Συσκευη χορηγησης φαρμακου
EE04216B1 (et)	2004-02-16	Vedel polümeerne kompositsioon ning selle kasutamine ravimina, mis on ette nähtud hüdrofoobse bioaktiivse aine reguleeritud vabastamiseks loomorganismis
ES2120543T3 (es)	1998-11-01	Dispositivo para la aplicacion de injertos.
DE69635734D1 (de)	2006-04-06	Verbesserte formulierung zur gesteuerten arzneistofffreisetzung durch kombination hydrophiler und hydrophober stoffe
DK1125577T3 (da)	2006-06-19	Væskeformige medikamentindföringspræparater
WO2001030323A3 (en)	2002-02-21	Controlled-release biocompatible ocular drug delivery implant devices and methods
EP0657152A3 (de)	1995-08-02	Verfahren und Vorrichtung zur Verhinderung einer hinteren Linsenkapseltrübung.
DK0654256T3 (da)	2000-12-18	Bionedbrydelig senehindetampon
ATE282406T1 (de)	2004-12-15	Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
DE69831940D1 (de)	2006-03-02	Tablette mit verlängerter Wirkstoffabgabe im Magen
ATE276768T1 (de)	2004-10-15	Arzneimittel gegen hepatitis
GEP20033078B (en)	2003-10-27	Controlled-Release Compositions of Betahistine
DK0954341T3 (da)	2007-06-11	Intrakulær linse med frigivelig medicinering
ES2178631T3 (es)	2003-01-01	Composicion a base de un oligomero y un polimero, inyectable y biodegradable.
DE60001717D1 (de)	2003-04-24	Mikrokapseln mit verzögerter freisetzung von wirkstoffen
CA2544460A1 (en)	2001-05-03	Controlled-release biocompatible ocular drug delivery implant devices and methods
CA2269774A1 (en)	1998-05-07	Apparatus for preventing posterior capsular opacification
CY1107201T1 (el)	2012-05-23	Ρυθμισμενη απο αμινοξεα μορφη δοσολογιας παρατεταμενης αποδεσμευσης
AR028670A1 (es)	2003-05-21	IMPLANTE DE TOXINA BOTULíNICA